| Oct 3 |
Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy
|
| Sep 3 |
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
|
| Aug 14 |
ABEO: Type A Meeting with FDA Concluded; BLA Submission on Track for 2H24…
|
| Aug 14 |
Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
|
| Aug 13 |
Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel
|
| Aug 12 |
Abeona Therapeutics: Q2 Earnings Snapshot
|
| Aug 12 |
Abeona Therapeutics GAAP EPS of -$0.26 beats by $0.10
|
| Aug 12 |
Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
|
| Aug 1 |
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Jul 21 |
Institutional investors own a significant stake of 39% in Abeona Therapeutics Inc. (NASDAQ:ABEO)
|
